These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 33590519)

  • 21. Polio eradication: the OPV paradox.
    Dowdle WR; De Gourville E; Kew OM; Pallansch MA; Wood DJ
    Rev Med Virol; 2003; 13(5):277-91. PubMed ID: 12931339
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Polio endgame: the global introduction of inactivated polio vaccine.
    Patel M; Zipursky S; Orenstein W; Garon J; Zaffran M
    Expert Rev Vaccines; 2015 May; 14(5):749-62. PubMed ID: 25597843
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reflections on Modeling Poliovirus Transmission and the Polio Eradication Endgame.
    Thompson KM; Kalkowska DA
    Risk Anal; 2021 Feb; 41(2):229-247. PubMed ID: 32339327
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Budget impact of polio immunization strategy for India: introduction of one dose of inactivated poliomyelitis vaccine and reductions in supplemental polio immunization.
    Khan MM; Sharma S; Tripathi B; Alvarez FP
    Public Health; 2017 Jan; 142():31-38. PubMed ID: 28057194
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Poliomyelitis prevention in the United States: introduction of a sequential vaccination schedule of inactivated poliovirus vaccine followed by oral poliovirus vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP).
    MMWR Recomm Rep; 1997 Jan; 46(RR-3):1-25. PubMed ID: 9026708
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Communications, Immunization, and Polio Vaccines: Lessons From a Global Perspective on Generating Political Will, Informing Decision-Making and Planning, and Engaging Local Support.
    Menning L; Garg G; Pokharel D; Thrush E; Farrell M; Kodio FK; Veira CL; Wanyoike S; Malik S; Patel M; Rosenbauer O
    J Infect Dis; 2017 Jul; 216(suppl_1):S24-S32. PubMed ID: 28838189
    [TBL] [Abstract][Full Text] [Related]  

  • 27. National choices related to inactivated poliovirus vaccine, innovation and the endgame of global polio eradication.
    Thompson KM; Duintjer Tebbens RJ
    Expert Rev Vaccines; 2014 Feb; 13(2):221-34. PubMed ID: 24308581
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Global Transmission of Live Polioviruses: Updated Dynamic Modeling of the Polio Endgame.
    Kalkowska DA; Pallansch MA; Wassilak SGF; Cochi SL; Thompson KM
    Risk Anal; 2021 Feb; 41(2):248-265. PubMed ID: 31960533
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness of incorporating inactivated poliovirus vaccine into the routine childhood immunization schedule.
    Miller MA; Sutter RW; Strebel PM; Hadler SC
    JAMA; 1996 Sep; 276(12):967-71. PubMed ID: 8805731
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Introduction of inactivated poliovirus vaccine into oral poliovirus vaccine-using countries.
    Wkly Epidemiol Rec; 2003 Jul; 78(28):241-50. PubMed ID: 15571166
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of potential non-synchronous cessation.
    Duintjer Tebbens RJ; Hampton LM; Thompson KM
    BMC Infect Dis; 2016 May; 16():231. PubMed ID: 27230071
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Polio Eradication and Endgame Plan - Victory within Grasp.
    Patel M; Menning L; Bhatnagar P
    Indian Pediatr; 2016 Aug; 53 Suppl 1():S28-S32. PubMed ID: 27771636
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The costs of future polio risk management policies.
    Tebbens RJ; Sangrujee N; Thompson KM
    Risk Anal; 2006 Dec; 26(6):1507-31. PubMed ID: 17184394
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Modeling Poliovirus Transmission in Pakistan and Afghanistan to Inform Vaccination Strategies in Undervaccinated Subpopulations.
    Duintjer Tebbens RJ; Pallansch MA; Cochi SL; Ehrhardt DT; Farag NH; Hadler SC; Hampton LM; Martinez M; Wassilak SGF; Thompson KM
    Risk Anal; 2018 Aug; 38(8):1701-1717. PubMed ID: 29314143
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Health Economic Analysis of Antiviral Drugs in the Global Polio Eradication Endgame.
    Badizadegan K; Kalkowska DA; Thompson KM
    Med Decis Making; 2023; 43(7-8):850-862. PubMed ID: 37577803
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Polio vaccines, eradication and posterradication].
    Salmerón García F; Portela Moreira A; Soler Soneira M; López Hernández S; Chamorro Somoza Díaz-Sarmiento M; Pérez González I; Rubio Gómez MI; Pérez González A; Sagredo Rodríguez A; Ruiz Antúnez S; Timón Jiménez M; Frutos Cabanillas G
    Rev Esp Salud Publica; 2013; 87(5):497-505. PubMed ID: 24322286
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Managing population immunity to reduce or eliminate the risks of circulation following the importation of polioviruses.
    Thompson KM; Kalkowska DA; Duintjer Tebbens RJ
    Vaccine; 2015 Mar; 33(13):1568-77. PubMed ID: 25701673
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Economics of polio vaccination in the post-eradication era: should OPV-using countries adopt IPV?
    Khan MM
    Vaccine; 2008 Apr; 26(16):2034-40. PubMed ID: 18339460
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Polio Endgame: Lessons Learned From the Immunization Systems Management Group.
    Zipursky S; Vandelaer J; Brooks A; Dietz V; Kachra T; Farrell M; Ottosen A; Sever JL; Zaffran MJ
    J Infect Dis; 2017 Jul; 216(suppl_1):S9-S14. PubMed ID: 28838174
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The role of Sabin inactivated poliovirus vaccine in the final phase of global polio eradication].
    Dong SZ; Zhu WB
    Zhonghua Yu Fang Yi Xue Za Zhi; 2016 Dec; 50(12):1032-1035. PubMed ID: 28057104
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.